|
Total: $257M |
||||
|
Company |
Location |
Date |
Amt. (M) |
Details |
|
Aires Pharma-ceuticals Inc. |
San Diego |
11/15 |
$20 |
Aires raised $20M in a Series B round led by MPM Capital, and including ProQuest Investments |
|
Beech Tree Labs Inc. |
Providence, R.I. |
11/17 |
$7 |
Beech Tree raised $7M in a Series B round |
|
Biodesix Inc. |
Broomfield, Colo. |
11/11 |
$7.1 |
Biodesix raised $7.1M through existing investors |
|
Ceregene Inc. |
San Diego |
11/12 |
$11.5 |
Ceregene closed a Series D round worth $11.5M in preferred stock; it was led by Hamilton BioVentures and Alta Partners with MPM Capital and Investor Growth Capital participating |
|
Cerulean Pharma Inc. |
Cambridge, Mass. |
11/16 |
$24 |
Cerulean raised $24M in a Series C round led by Lilly Ventures, and including Polar Venture Partners, Venrock, Lux Capital and Bessemer Venture Partners |
|
Coronado Biosciences Inc. |
New York |
11/5 |
$21.6 |
Coronado raised $21.6M through a financing led by Paramount BioCapital Inc. |
|
Delenex Therapeutics AG |
Zurich, Switzerland |
11/15 |
CHF13.5 ($14.8) |
Delenex secured $14.8M in a Series A round led by SV Life Sciences, HBM BioCapital, HBM BioVentures, BioMedInvest and VI Partners |
|
Helix Therapeutics LLC |
Newhaven, Conn. |
11/24 |
$2.5 |
Helix raised $2.5M through an investment from Canaan Partners and Connecticut Innovations |
|
Hutchison MediPharma Holdings Ltd. |
London |
11/9 |
$12.5 |
Hutchison raised $12.5M via a private investment from Mitsui & Co. Ltd. |
|
Karyopharm Therapeutics Inc. |
Newton, Mass. |
11/4 |
$20 |
Karyopharm raised $20M through a Series A financing from Chione Ltd. |
|
Mind-NRG SA |
Geneva, Switzerland |
11/3** |
€1.5 ($2.1) |
Mind-NRG raised $2.1M in an initial investment from Index Ventures |
|
Mtm Laboratories AG |
Heidelberg, Germany |
11/9 |
€7 ($9.7) |
Mtm raised an additional $9.7M in its Series C round led by HBM BioVentures Ltd., Wellington Partners and Gilde Healthcare Partners, with a consortium including National Technology Enterprises Co., Heidelberg Innovation and private investors |
|
RedHill Biopharma Ltd. |
Tel Aviv, Israel |
11/9 |
$10 |
RedHill raised $10M in a private placement |
|
Sutro Biopharma Inc. |
San Francisco |
11/18 |
$36.5 |
Sutro raised $36.5M in a Series C led by Skyline Ventures; other investors were the corporate venture arms of Eli Lilly and Co. and Amgen Inc., SV Life Sciences and Alta Partners |
|
Syntaxin Ltd. |
Oxford, UK |
11/12 |
£18 ($29) |
Syntaxin closed a $29M financing that included Abingworth, SROne, LSP, Johnson & Johnson Development Corp. and Quest, as well as Lundbeckfond Ventures and Ipsen and Seventure |
|
Verastem Inc. |
Boston |
11/17 |
$16 |
Verastem closed a $16M Series A round led by Longwood Founders Fund; Bessemer Venture Partners, Cardinal Partners and MPM Capital joined in the financing |
|
Xention Ltd. |
Cambridge, UK |
11/24 |
£8 ($12.7) |
Xention raised $12.7M in a Series D financing led by Seroba-Kernel Life Sciences Ltd., and including existing investors Forbion Capital Partners, Credit Agricole Private Equity, MVM and BTG International |
|
Notes: Currency conversions are based on exchange rates at the time of the deal. ** Denotes the date the item ran in BioWorld International. The date indicated refers to the BioWorld Today issue in which the news item can be found. ND = Not disclosed. |
||||